Suppression of Myc oncogenic activity by nucleostemin haploinsufficiency

Oncogene

Volumn 31, Issue 28, 2012, Pages 3311-3321

  Zwolinska, A K ^a,b   Heagle Whiting, A ^c   Beekman, C ^a   Sedivy, J M ^c   Marine, J C ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c BROWN UNIVERSITY   (United States)

Author keywords

c Myc; lymphoma; nucleostemin; p53; transgenic mice

Indexed keywords

MYC PROTEIN; PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; B CELL LYMPHOMA; CANCER CELL CULTURE; CELL PROLIFERATION; CELL TRANSFORMATION; CHROMATIN IMMUNOPRECIPITATION; DISEASE COURSE; DOWNSTREAM PROCESSING; E BOX ELEMENT; GENE ACTIVITY; GENE EXPRESSION; GENE FUNCTION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HAPLOINSUFFICIENCY; HUMAN; HUMAN CELL; IN VIVO STUDY; LIFESPAN; NONHUMAN; NUCLEOSTEMIN GENE; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEFICIENCY; TRANSGENIC MOUSE; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GTP-BINDING PROTEINS; HAPLOINSUFFICIENCY; HUMANS; LYMPHOMA; MICE; NUCLEAR PROTEINS; ONCOGENES; PROTO-ONCOGENE PROTEINS C-MYC; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

MUS; MUS MUSCULUS;

EID: 84863792301     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.507     Document Type: Article

References (70)

1. Adams JM, Harris AW, Langdon WY, Pinkert CA, Brinster RL, Palmiter RD et al. (1986). c-myc-induced lymphomagenesis in transgenic mice and the role of the Pvt-1 locus in lymphoid neoplasia. Curr Top Microbiol Immunol 132: 1-8.
2. Adhikary S, Eilers M. (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645. (Pubitemid 41081267)
3. Askew DS, Ashmun RA, Simmons BC, Cleveland JL. (1991). Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6: 1915-1922. (Pubitemid 21924028)
4. Barna M, Pusic A, Zollo O, Costa M, Kondrashov N, Rego E et al. (2008). Suppression of Myc oncogenic activity by ribosomal protein haploinsufficiency. Nature 456: 971-975.
5. Beekman C, Nichane M, De Clercq S, Maetens M, Floss T, Wurst W et al. (2006). Evolutionarily conserved role of nucleostemin: controlling proliferation of stem/progenitor cells during early vertebrate development. Mol Cell Biol 26: 9291-9301. (Pubitemid 44904424)
6. Bernardi R, Pandolfi PP. (2003). The nucleolus: at the stem of immortality. Nat Med 9: 24-25. (Pubitemid 36098255)
7. Bouchard C, Staller P, Eilers M. (1998). Control of cell proliferation by Myc. Trends Cell Biol 8: 202-206. (Pubitemid 28188115)
8. Brodsky AS, Meyer CA, Swinburne IA, Hall G, Keenan BJ, Liu XS et al. (2005). Genomic mapping of RNA polymerase II reveals sites of co-transcriptional regulation in human cells. Genome Biol 6: R64.
9. Brown JP, Wei W, Sedivy JM. (1997). Bypass of senescence after disruption of p21 CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277: 831-834. (Pubitemid 27366737)
10. Chao C, Saito S, Anderson CW, Appella E, Xu Y. (2000). Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 97: 11936-11941.
11. Chen Y, Olopade OI. (2008). MYC in breast tumor progression. Expert Rev Anticancer Ther 8: 1689-1698.
12. Dai MS, Lu H. (2004). Inhibition of MDM2-mediated p53 ubiquitination and degradation by ribosomal protein L5. J Biol Chem 279: 44475-44482.
13. Dai MS, Sun XX, Lu H. (2008). Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 28: 4365-4376.
14. Dai MS, Zeng SX, Jin Y, Sun XX, David L, Lu H. (2004). Ribosomal protein L23 activates p53 by inhibiting MDM2 function in response to ribosomal perturbation but not to translation inhibition. Mol Cell Biol 24: 7654-7668. (Pubitemid 39121491)
15. Dang CV, O'Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. (2006). The c-Myc target gene network. Semin Cancer Biol 16: 253-264. (Pubitemid 44311039)
16. Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ et al. (2006). Molecular diagnosis of Burkitt's lymphoma. N Engl J Med 354: 2431-2442. (Pubitemid 43855046)
17. De Clercq S, Gembarska A, Denecker G, Maetens M, Naessens M, Haigh K et al. (2010). Widespread overexpression of epitope-tagged Mdm4 does not accelerate tumor formation in vivo. Mol Cell Biol 30: 5394-5405.
18. Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M et al. (2007). Non-transcriptional control of DNA replication by c-Myc. Nature 448: 445-451. (Pubitemid 47123512)
19. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS et al. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
20. Eilers M, Eisenman RN. (2008). Myc's broad reach. Genes Dev 22: 2755-2766.
21. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. (1999). Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 13: 2658-2669. (Pubitemid 29508553)
22. Eischen CM, Woo D, Roussel MF, Cleveland JL. (2001). Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol 21: 5063-5070. (Pubitemid 32656403)
23. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M et al. (1992). Induction of apoptosis in fibroblasts by c-myc protein. Cell 69: 119-128.
24. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. (2003). Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129. (Pubitemid 36534986)
25. Frank SR, Schroeder M, Fernandez P, Taubert S, Amati B. (2001). Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 15: 2069-2082. (Pubitemid 32762051)
26. Han C, Zhang X, Xu W, Wang W, Qian H, Chen Y. (2005). Cloning of the nucleostemin gene and its function in transforming human embryonic bone marrow mesenchymal stem cells into F6 tumor cells. Int J Mol Med 16: 205-213.
27. Huang M, Itahana K, Zhang Y, Mitchell BS. (2009). Depletion of guanine nucleotides leads to the Mdm2-dependent proteasomal degradation of nucleostemin. Cancer Res 69: 3004-3012.
28. Hursting SD, Perkins SN, Phang JM. (1994). Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 91: 7036-7040. (Pubitemid 24226797)
29. Izumi H, Molander C, Penn LZ, Ishisaki A, Kohno K, Funa K. (2001). Mechanism for the transcriptional repression by c-Myc on PDGF beta-receptor. J Cell Sci 114: 1533-1544. (Pubitemid 32427839)
30. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT et al. (1994). Tumor spectrum analysis in p53-mutant mice. Curr Biol 4: 1-7.
31. Jafarnejad SM, Mowla SJ, Matin MM. (2008). Knocking-down the expression of nucleostemin significantly decreases rate of proliferation of rat bone marrow stromal stem cells in an apparently p53-independent manner. Cell Prolif 41: 28-35.
32. Jin A, Itahana K, O'Keefe K, Zhang Y. (2004). Inhibition of HDM2 and activation of p53 by ribosomal protein L23. Mol Cell Biol 24: 7669-7680. (Pubitemid 39121492)
33. Kidder BL, Yang J, Palmer S. (2008). Stat3 and c-Myc genome-wide promoter occupancy in embryonic stem cells. PLoS One 3: e3932.
34. Kim J, Lee JH, Iyer VR. (2008). Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its Ebox usage in vivo. PLoS One 3: e1798.
35. Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. (2003). A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells. Proc Natl Acad Sci USA 100: 8164-8169. (Pubitemid 36842516)
36. Lin T, Meng L, Li Y, Tsai RY. (2010). Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res 70: 9444-9452.
37. Liu SJ, Cai ZW, Liu YJ, Dong MY, Sun LQ, Hu GF et al. (2004). Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J Gastroenterol 10: 1246-1249.
38. Lo D, Lu H. (2010). Nucleostemin: Another nucleolar 'Twister' of the p53-MDM2 loop. Cell Cycle 9: 3227-3232.
39. Mai S, Fluri M, Siwarski D, Huppi K. (1996). Genomic instability in MycER-activated Rat1A-MycER cells. Chromosome Res 4: 365-371. (Pubitemid 26273353)
40. Malakootian M, Mowla SJ, Saberi H, Asadi MH, Atlasi Y, Shafaroudi AM. (2010). Differential expression of nucleostemin, a stem cell marker, and its variants in different types of brain tumors. Mol Carcinog 49: 818-825.
41. Mao DY, Watson JD, Yan PS, Barsyte-Lovejoy D, Khosravi F, Wong WW et al. (2003). Analysis of Myc bound loci identified by CpG island arrays shows that Max is essential for Myc-dependent repression. Curr Biol 13: 882-886. (Pubitemid 36573259)
42. Marine JC. (2010). Pharmacological rescue of p53 in cancer therapy: widening the sensitive tumor spectrum by targeting MDMX. Cancer Cell 18: 399-400.
43. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. (1997). Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 8: 1039-1048. (Pubitemid 27433292)
44. Mateyak MK, Obaya AJ, Sedivy JM. (1999). c-Myc regulates cyclin D-cdk4 and -cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol 19: 4672-4683. (Pubitemid 29289505)
45. Meyer N, Kim SS, Penn LZ. (2006). The Oscar-worthy role of Myc in apoptosis. Semin Cancer Biol 16: 275-287. (Pubitemid 44321974)
46. O'Connell BC, Cheung AF, Simkevich CP, Tam W, Ren X, Mateyak MK et al. (2003). A large scale genetic analysis of c-Myc-regulated gene expression patterns. J Biol Chem 278: 12563-12573. (Pubitemid 36800246)
47. Perna D, Faga G, Verrecchia A, Gorski MM, Barozzi I, Narang V et al. (2011). Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene (e-pub ahead of print 22 August 2011; doi:10.1038/onc.2011.359).
48. Prouty SM, Hanson KD, Boyle AL, Brown JR, Shichiri M, Follansbee MR et al. (1993). A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene 8: 899-907. (Pubitemid 23087421)
49. Qi Y, Gregory MA, Li Z, Brousal JP, West K, Hann SR. (2004). p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431: 712-717. (Pubitemid 39382620)
50. Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA et al. (2006). MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res 66: 6598-6605. (Pubitemid 44085615)
51. Romanova L, Grand A, Zhang L, Rayner S, Katoku-Kikyo N, Kellner S et al. (2009). Critical role of nucleostemin in pre-rRNA processing. J Biol Chem 284: 4968-4977.
52. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346: 1937-1947. (Pubitemid 34651353)
53. Schorl C, Sedivy J. (2003). Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell 14: 823-835. (Pubitemid 36337435)
54. Seoane J, Le HV, Massague J. (2002). Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature 419: 729-734. (Pubitemid 35177959)
55. Shaffer AL, Wright G, Yang L, Powell J, Ngo V, Lamy L et al. (2006). A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev 210: 67-85.
56. Sijin L, Ziwei C, Yajun L, Meiyu D, Hongwei Z, Guofa H et al. (2004). The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp Clin Cancer Res 23: 529-538. (Pubitemid 39490640)
57. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H et al. (2001). Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol 3: 392-399. (Pubitemid 32288447)
58. Toledo F, Wahl GM. (2007). MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 39: 1476-1482. (Pubitemid 47031042)
59. Tsai RY, McKay RD. (2002). A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 16: 2991-3003. (Pubitemid 35424188)
60. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM et al. (2002). c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogeneinduced genetic instability. Mol Cell 9: 1031-1044. (Pubitemid 34626672)
61. van Riggelen J, Muller J, Otto T, Beuger V, Yetil A, Choi PS et al. (2010). The interaction between Myc and Miz1 is required to antagonize TGFbeta-dependent autocrine signaling during lymphoma formation and maintenance. Genes Dev 24: 1281-1294.
62. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A et al. (2002). Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
63. Vita M, Henriksson M. (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330. (Pubitemid 44311040)
64. Wang JH, Alt FW, Gostissa M, Datta A, Murphy M, Alimzhanov MB et al. (2008). Oncogenic transformation in the absence of Xrcc4 targets peripheral B cells that have undergone editing and switching. J Exp Med 205: 3079-3090.
65. Wei W, Jobling WA, Chen W, Hahn WC, Sedivy JM. (2003). Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol 23: 2859-2870. (Pubitemid 36403083)
66. Ye F, Zhou C, Cheng Q, Shen J, Chen H. (2008). Stem-cell-abundant proteins Nanog, nucleostemin and musashi1 are highly expressed in malignant cervical epithelial cells. BMC Cancer 8: 108.
67. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT et al. (2006). Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103: 17834-17839. (Pubitemid 44852246)
68. Zhang J, Wang JH. (2010). Characterization of differential properties of rabbit tendon stem cells and tenocytes. BMC Musculoskelet Disord 11: 10.
69. Zhang X, DeSalle LM, Patel JH, Capobianco AJ, Duonan Y, Thomas-Tikhonenko A et al. (2005). Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-Myc oncoprotein. PNAS 102: 13969-13973.
70. Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ et al. (1998). Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev 12: 2424-2433. (Pubitemid 28371361)